Cancer
Malignant Prostate Neoplasm
CI-CAN-00005927Explore in graph →
Top-level1,377 active trials24 approved drugs58 evidence items
- NCIt
- C7378
- ICD-10
- C61
- DOID
- 10283
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00005927Explore in graph →
Clinical trials
5,981 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (730)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06450106 | Study of STM-416p Administered to Patients Undergoing Radical Prostatectomy | recruiting | Phase 1 | 18 | SURGE TherapeuticsINDUSTRY | 2 | Feb 19, 2026 | clinicaltrials |
| NCT07339267 | A Study to Evaluate the Safety and Drug Levels of ASP5541 in Chinese Participants With Prostate Cancer | recruiting | Phase 1 | 12 | Astellas Pharma Global Development, Inc.INDUSTRY | 1 | Feb 18, 2026 | clinicaltrials |
| NCT06778863 | A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation(GUARDIAN-101) | recruiting | Phase 1 | 90 | Clasp Therapeutics, Inc.INDUSTRY | 1 | Feb 13, 2026 | clinicaltrials |
| NCT04478279 | A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 125 | Sapience TherapeuticsINDUSTRY | 2 | Feb 9, 2026 | clinicaltrials |
| NCT06631521 | Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate Cancer | recruiting | Phase 1 | 30 | AdventHealthOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT04729114 | A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer | recruiting | Phase 1 | 174 | Astellas Pharma Global Development, Inc.INDUSTRY | 2 | Feb 4, 2026 | clinicaltrials |
| NCT05864196 | Two Fraction Prostate SBRT With DIL SIB | recruiting | Phase 1 | 80 | NYU Langone HealthOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT06636123 | GZ17-6.02 in Advanced CRPC After Progression on Anti-Androgen Therapy | recruiting | Phase 1 | 30 | Virginia Commonwealth UniversityOTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT07363382 | The Value of GRPR PET Imaging for Diagnosis and Staging in Prostate Cancer | recruiting | Phase 1 / Phase 2 | 6 | First Affiliated Hospital of Fujian Medical UniversityOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT07363486 | Sequential Study of 225Ac-LNC1011 in the Treatment of Metastatic Castration-Resistant Prostate Cancer | recruiting | Phase 1 / Phase 2 | 9 | First Affiliated Hospital of Fujian Medical UniversityOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT07358806 | Study to Assess the Effect of OCT-598 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 51 | Oscotec Inc.INDUSTRY | 1 | Jan 22, 2026 | clinicaltrials |
| NCT06830850 | A Trial of HRS-5041-103 to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-5041 in Subjects With Metastatic Castration-resistant Prostate Cancer | recruiting | Phase 1 | 25 | Atridia Pty Ltd.INDUSTRY | 1 | Jan 15, 2026 | clinicaltrials |
| NCT06334432 | Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 466 | Nuvation Bio Inc.INDUSTRY | 1 | Jan 14, 2026 | clinicaltrials |
| NCT07181473 | A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors | recruiting | Phase 1 | 200 | Phrontline BiopharmaINDUSTRY | 2 | Jan 12, 2026 | clinicaltrials |
| NCT04686682 | A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors | recruiting | Phase 1 / Phase 2 | 152 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 9, 2026 | clinicaltrials |
| NCT05570994 | 177Lu-HTK03170 in mCRPC With PSMA Positive Disease | enrolling by invitation | Phase 1 / Phase 2 | 50 | British Columbia Cancer AgencyOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT05010200 | The Safety and Tolerability of PGV001-based Personalized Multi-peptide Vaccines in the Adjuvant Setting.(PGV-Prostate) | active not recruiting | Phase 1 | 27 | Ashutosh Kumar TewariOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT06970119 | A Multicenter, Open-label, Non-randomized Phase I/IIa Clinical Trial to Evaluate INR102 Injection in Patients With Prostate Cancer | recruiting | Phase 1 / Phase 2 | 55 | Yunhe Pharmaceutical (Tianjin) Co., LtdOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT06531499 | A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study(RADIODOSE) | recruiting | Phase 1 | 106 | Novartis PharmaceuticalsINDUSTRY | 6 | Dec 31, 2025 | clinicaltrials |
| NCT07310355 | 68Ga-PSMA-0057 and 177Lu-PSMA-0057 in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer | not yet recruiting | Phase 1 / Phase 2 | 49 | Chengdu StarRay Therapeutics Co., LtdINDUSTRY | 0 | Dec 30, 2025 | clinicaltrials |
| NCT06155084 | A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in mCRPC Patients | recruiting | Phase 1 / Phase 2 | 84 | Hinova Pharmaceuticals Inc.INDUSTRY | 1 | Dec 22, 2025 | clinicaltrials |
| NCT06229366 | [Ac-225]-PSMA-62 Trial in Oligometastatic Hormone Sensitive and Metastatic Castration Resistant Prostate Cancer(ACCEL) | active not recruiting | Phase 1 | 142 | Eli Lilly and CompanyINDUSTRY | 1 | Dec 22, 2025 | clinicaltrials |
| NCT06943521 | A Study of MT-4561 in Patients With Various Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 27 | Tanabe Pharma America, Inc.INDUSTRY | 2 | Dec 11, 2025 | clinicaltrials |
| NCT06105918 | Radioligand Therapy After PSMA PET Guided External Beam Radiotherapy for Treating Post-Prostatectomy Patients With Biochemically Recurrent Prostate Cancer | active not recruiting | Phase 1 | 6 | Emory UniversityOTHER | 1 | Dec 9, 2025 | clinicaltrials |
| NCT07271017 | Robot-Assisted Prostate Biopsy With a Novel Ultrasound Probe | recruiting | Phase 1 | 60 | Johns Hopkins UniversityOTHER | 1 | Dec 8, 2025 | clinicaltrials |
| NCT07115446 | Phase Ib Study of HS-20093+HRS-5041 in Patients With Advanced Prostate Cancer | recruiting | Phase 1 | 63 | Hansoh BioMedical R&D CompanyINDUSTRY | 1 | Dec 5, 2025 | clinicaltrials |
| NCT03983954 | Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer. | active not recruiting | Phase 1 | 120 | NeoTX Therapeutics Ltd.INDUSTRY | 2 | Nov 28, 2025 | clinicaltrials |
| NCT02023463 | Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer | active not recruiting | Phase 1 | 25 | Thomas Jefferson UniversityOTHER | 1 | Nov 25, 2025 | clinicaltrials |
| NCT06400160 | Clinical Trial of TB511 in Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 12 | Twinpig Biolab, Inc.INDUSTRY | 0 | Nov 25, 2025 | clinicaltrials |
| NCT06126731 | Combination Study of Antibiotics With Enzalutamide (PROMIZE) | recruiting | Phase 1 / Phase 2 | 39 | Institute of Cancer Research, United KingdomOTHER | 2 | Nov 24, 2025 | clinicaltrials |
| NCT07244393 | Lutetium (177Lu) DGUL Combined With Pembrolizumab in Metastatic Castration-Resistant Prostate Cancer | not yet recruiting | Phase 1 | 30 | Cellbion Co., Ltd.INDUSTRY | 0 | Nov 24, 2025 | clinicaltrials |
| NCT03582475 | Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate | active not recruiting | Phase 1 | 15 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Nov 12, 2025 | clinicaltrials |
| NCT06062745 | Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CT | recruiting | Phase 1 | 30 | Brigham and Women's HospitalOTHER | 1 | Nov 5, 2025 | clinicaltrials |
| NCT05540392 | An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues | active not recruiting | Phase 1 / Phase 2 | 60 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 10, 2025 | clinicaltrials |
| NCT07172126 | Clinical Trial to Evaluate the Tolerance of TQB3201 Tablets | not yet recruiting | Phase 1 / Phase 2 | 291 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Sep 15, 2025 | clinicaltrials |
| NCT01655836 | High-Dose Rate Brachytherapy and Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer | active not recruiting | Phase 1 | 42 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Sep 11, 2025 | clinicaltrials |
| NCT05107674 | A Study of NX-1607 in Adults With Advanced Malignancies | recruiting | Phase 1 | 345 | Nurix Therapeutics, Inc.INDUSTRY | 2 | Sep 9, 2025 | clinicaltrials |
| NCT06689163 | A Study for the Treatment of Metastatic Prostate Cancer With HRS-1167 Tablets Combined With Abiraterone Acetate Tablets and Prednisone | recruiting | Phase 1 / Phase 2 | 66 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Sep 3, 2025 | clinicaltrials |
| NCT06703437 | Long Acting Neuraxial Peri-prostatic Block in Cancer | active not recruiting | Phase 1 | 12 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Sep 3, 2025 | clinicaltrials |
| NCT07149831 | A Clinical Trial Evaluating the Safety and Tolerability, Biodistribution and Radiation Dosimetry, and Pharmacokinetics of Flotufolastat F-18 Injection in Healthy Chinese Adults | recruiting | Phase 1 | 6 | Sinotau Pharmaceutical GroupINDUSTRY | 1 | Sep 2, 2025 | clinicaltrials |
| NCT03170960 | Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 | 914 | ExelixisINDUSTRY | 9 | Aug 17, 2025 | clinicaltrials |
| NCT05057013 | A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours | active not recruiting | Phase 1 / Phase 2 | 81 | Cancer Research UKOTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT07104617 | Study of TY-302 Capsules Combined With Abiraterone in Patients With Metastatic Castration-resistant Prostate Cancer（mCRPC） | not yet recruiting | Phase 1 / Phase 2 | 48 | TYK Medicines, IncINDUSTRY | 1 | Aug 5, 2025 | clinicaltrials |
| NCT06666270 | Study of SYN818 for the Treatment of Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 30 | Hangzhou SynRx Therapeutics Biomedical Technology Co., LtdINDUSTRY | 1 | Jul 20, 2025 | clinicaltrials |
| NCT06769425 | HS-10502 Combination Treatment in Patients With Advanced Solid Tumors(HS-10502) | recruiting | Phase 1 | 157 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 24, 2025 | clinicaltrials |
| NCT06383052 | A Phase 1/2 Study of 177Lu-NYM032 Injection in mCRPC | active not recruiting | Phase 1 / Phase 2 | 30 | Norroy Bioscience Co., LTDINDUSTRY | 1 | May 21, 2025 | clinicaltrials |
| NCT03874884 | 177Lu-PSMA-617 Therapy and Olaparib in Patients With Metastatic Castration Resistant Prostate Cancer(LuPARP) | active not recruiting | Phase 1 | 70 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | May 14, 2025 | clinicaltrials |
| NCT06139575 | Phase 1/2 Clinical Study of Lutetium Lu 177 JH020002 Injection in Patients With Advanced Prostate Cancer | recruiting | Phase 1 / Phase 2 | 90 | Bivision Pharmaceuticals, Inc.INDUSTRY | 1 | May 13, 2025 | clinicaltrials |
| NCT04186585 | Recommended Dose Estimation of BP-C2 | recruiting | Phase 1 | 8 | MeddocOTHER | 1 | May 9, 2025 | clinicaltrials |
| NCT04253262 | A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer | active not recruiting | Phase 1 / Phase 2 | 13 | Brown UniversityOTHER | 1 | May 4, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Feb 19, 2026source: clinicaltrials